All In Biotech

Drug Trial Radar · NCT05455619

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Study to Assess the Safety and Efficacy of Evexomostat (SDX-7320) in Combination With A PI3K or Akt Inhibitor Plus Fulvestrant in Patients With HR+, HER2-, Metastatic Breast Cancer With PI3K Pathway Alteration(s)

Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Aug 26, 2022

Primary completion

Dec 2026

Study completion Mar 2027

Sponsor

Lead sponsor
SynDevRx, Inc.Industry
Sponsor type
Industry
First posted
Jul 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2, open-label, parallel-arms pilot study in men and post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the PI3K pathway, including a mutation of the PIK3CA gene, PTEN loss, or AKT1 mutation, designed to determine the safety of evexomostat (SDX-7320) plus standard of care treatment alpelisib (BYL-719) or capivasertib and fulvestrant (each combined, the 'triplet therapy'), to measure the severity and number of hyperglycemic events, and to assess clinical, anti-tumor benefit of the triplet therapy. The purpose of this study is: * to characterize the safety of the triplet drug combination consisting of either alpelisib or capivasertib (per the treating oncologist's choice) and fulvestrant plus evexomostat, * to test whether evexomostat, when given in combination with either alpelisib or capivasertib and fulvestrant will reduce the number and severity of hyperglycemic events and/or reduce the number or dose of anti-diabetic medications needed to control the hyperglycemia for metabolically normal patients and those deemed at risk for capivasertib and alpelisib-induced hyperglycemia (insulin resistance, as measured by HOMA-IR, baseline elevated HbA1c or well-controlled type 2 diabetes), and * to assess preliminary anti-tumor efficacy for each combination and changes in key biomarkers and quality of life in this patient population.

Conditions

  • HR+/HER2-negative Breast Cancer
  • Metastatic Breast Cancer

Interventions

  • EvexomostatDrug

    Evexomostat (SDX-7320) is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse EventsTime frame: Up to 48 months
  2. Hyperglycemic EventsTime frame: Up to 42 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Loma Linda University Cancer Center

    Loma Linda, California · Recruiting

  • Hoag Memorial Hospital Presbyterian

    Newport, California · Recruiting

  • SHARP Healthcare

    San Diego, California · Recruiting

  • Miami Cancer Institute at Baptist Health

    Miami, Florida · Recruiting

  • Hope and Healing Cancer Services

    Hinsdale, Illinois · Recruiting

  • Trinity Health

    Ypsilanti, Michigan · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Penn State Milton S Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Doctors Hospital of Laredo

    Laredo, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.